Not sure,
But even in the unlikely event of a full rebate, it will fade into insignificance alongside near term potential revenue.
In a very recently conversation with management, it was stated that while both Brian and Tony were very happy to have Morgan's report on ResApp, they both felt that revenue and projected timeframes were ultra, ultra conservative. Almost unrealistically conservative.
But of course they also understood that Morgan's would prefer that any investors acting on their cue be pleasantly surprised, rather than bitterly disappointed. So it is all good.
Morgan's amongst others, are supporting the BioShares Biotech Summit in Queenstown NZ, set to kick off tomorrow. Of course ResApp will be present!
On a side note, it is great to see a high volume of shares swap hands at these levels. As new holders bring the avg price paid per share up, this continues to put less downward pressure on ResApp as we move forward. After all people buying at these levels are unlikely to push the SP down to levels lower than this.
In saying all this, ResApp has global significance and if good results come out and this is significantly de-risked, this will likely start to make a steady climb in anticipation of FDA approval, buoyed by global institutions. With good results, the next leg up is to 'unicorn status and beyond'.
Over time, less and less shares will be held by Aussie investors.
Insto's will be doing much of the mopping up of loose shares.
Good results will prove this is, without reason of doubt, completely feasible and any delay will be due to teething issues, not a risk of collapse.
Doubters will no longer be able to find any reason to suggest that RAP is an 'ALL or NOTHING' stock. At the most they will be able to caste doubt on timeframes for this to multi-bag.
If you snooze you lose: waiting for confirmation of earnings might win accolades from Motley Fools, but chances of grabbing a multi bagger are close to zilch.
Fidelity has been happy to take a significant stake prior to the FDA trials even commencing.
This is significant.
So upon further de-risking from good US trial results, who here thinks other global insto's will sit on their hands? Who here thinks the SP will sit flat from here up until a response from the FDA?
For the record- NOT ME.
Cheers
CT
Expand
